Percutaneous AngioVac Vegetation Extraction (PAVE) to Remove Right Heart Vegetations in Patients With Infective Endocarditis
← catalyst calendarNCT07282002 · readout ≤ 103 d
Sponsored by Angiodynamics, Inc. (industry) · ANGO — their whole pipeline →.
Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
30estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Apr 2026 | estimated | When the study began enrolling |
| Primary completion | Nov 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Mar 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Infective Endocarditis (IE)
Intervention
- Device: AngioVac System
Primary outcomes
what the primary-completion date above is the date OFRate of Clinical Success
measured 30 days post-procedure
Rate of Major Adverse Events (MAEs)
measured 48 hours post-procedure
Permalink · ANGO's whole pipeline · Catalyst calendar · Every registered study · What changed